45th week of 2011 patent applcation highlights part 33 |
Patent application number | Title | Published |
20110274618 | DIAGNOSTIC AND/OR THERAPEUTIC AGENT, METHOD FOR THE MANUFACTURE THEREOF AND USE THEREOF - The invention relates to the fields of materials sciences and medicine and relates to an agent, which can be used, for example, as a contrast medium for the localization of cancer cells. The object of the present invention is to disclose an agent which sensitively and selectively recognizes the site and the type of the molecules or cells to be examined. The object is attained through an agent composed at least of bio-shuttle molecules to which endohedral fullerenes are coupled by way of peptide-based molecules, wherein the endohedral fullerenes are hydrophobic and correspond to the formula A | 2011-11-10 |
20110274619 | BRAIN TUMOR TARGETING PEPTIDES AND METHODS - A method of diagnosing and treating a human glioblastoma multiforme (GBM) brain tumor in a subject is disclosed. The method includes administering to the subject, an effective amount of composition having a peptide 12-20 amino acid residues in length and selected for its ability to bind preferentially to a subtype of human GBM cells identified as brain tumor initiating cells (BTICs) or highly invasive glioma cells (HIGCs). | 2011-11-10 |
20110274620 | MULTIFUNCTIONAL DEGRADABLE NANOPARTICLES WITH CONTROL OVER SIZE AND FUNCTIONALITIES - In one aspect, the invention relates to polymers, crosslinked polymers, functionalized polymers, nanoparticles, and functionalized nanoparticles and methods of making and using same. In one aspect, the invention relates to degradable polymers and degradable nanoparticles. In one aspect, the invention relates to methods of preparing degradable nanoparticles and, more specifically, methods of controlling particle size during the preparation of degradable nanoparticles. In one aspect, the degradable nanoparticles are useful for complexing, delivering, and releasing payloads, including pharmaceutically active payloads. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 2011-11-10 |
20110274621 | Active Particles for Bio-Analytical Applications and Methods for Their Preparation - Nanoparticles, which are luminescent and/or electroactive and/or suitable for MRI (magnetic resonance imaging and/or PET (positron emission tomography) applications, comprise a micelle, which has a hydrophilic shell and an hydrophobic central portion, and a polysilicate core; the micelle comprises a plurality of molecules of a functionalized surfactant having the following structure: M | 2011-11-10 |
20110274622 | Nanocrystal Nano-Emulsion - The invention relates to a nanocrystal formulation in the form of a nano-emulsion, comprising a continuous aqueous phase and at least one dispersed oily phase, in which the oily phase comprises at least one amphiphilic lipid and at least one solubilising lipid, and in which the aqueous phase comprises a cosurfactant. | 2011-11-10 |
20110274623 | Stabilized Fibronectin Domain Compositions, Methods and Uses - A protein scaffold based on a consensus sequence of fibronectin type III (FN3) proteins, such as the tenth FN3 repeat from human fibronectin (human Tenascin), including isolated nucleic acids that encode a protein scaffold, vectors, host cells, and methods of making and using thereof, exhibit enhanced thermal and chemical stability while presenting six modifiable loop domains which can be engineered to form a binding partner capable of binding to a target for applications in diagnostic and/or therapeutic compositions, methods and devices. | 2011-11-10 |
20110274624 | CONTRAST AGENTS IN POROUS PARTICLES - MRI imaging compositions are disclosed comprising non-chelated MRI contrast agents in the pores of at least one porous microparticle or nanoparticle. The compositions of the invention have been found to exhibit increased relaxivity and therefore, enhanced MRI imaging. The non-chelated contrast agents include T1 contrast agents, such as those including Gd(III) or Mn(II). Methods of MRI imaging and methods of making the compositions are also disclosed. | 2011-11-10 |
20110274625 | Liposomal Composition for Convection-Enhanced Delivery to the Central Nervous Centre - Convection-enhanced delivery (CED) is used as a method to deliver a direct infusion of therapeutic agents to the central nervous centre thus circumventing the blood-blood barrier. A non-PEGylated liposomal composition comprising at least one saturated neutral phospholipid and at least one saturated anionic phospholipid and a therapeutic or diagnostic agent encapsulated therein is used to overcome toxicity associated with high peak drug concentration delivered locally CED as well as to increase tissue distribution volume for an improved sustained drug release. In one embodiment, the liposome composition comprises a molar ratio of DSPC:DSPG:CHOL of 7:2:1 and the therapeutic or diagnostic agent is selected from topotecan, conotoxin, gadodiamide or rhodamine, and is used in the treatment of epilepsy | 2011-11-10 |
20110274626 | PULSE SEQUENCING WITH HYPERPOLARISABLE NUCLEI - There is described a method of selective observation of non-hydrogenative para-hydrogen induced polarisation (NH-PHIP) as enhanced magnetic resonance signals which comprises separating the thermal and longitudinal spin order states. There is also described a template comprising [Ir(COD)(NHC)(Py)] | 2011-11-10 |
20110274627 | Method Of Making An Aerosol Shave Composition Comprising A Hydrophobical Agent Forming At Least One Microdroplet - A process of making an aerosol shave composition, preferably a post foaming shave gel, comprising a hydrophobic agent, such as a silicon, in the form of a microdroplet having a particle size from about 0.15 microns to about 10 microns. | 2011-11-10 |
20110274628 | NICOTINE-CONTAINING PHARMACEUTICAL COMPOSITIONS - A composition intended to be employed for therapeutic purposes incorporates nicotine and at least one other nicotinic compound. Representative forms of nicotine can be as a free base (e.g., as a mixture of nicotine and microcrystalline cellulose), as a form of nicotine salt (e.g., as nicotine bitartrate) or as nicotine polacrilex. The other nicotinic compound is a compound that can be considered to bind selectively to certain nicotinic receptor subtypes, and particularly those of the central nervous system. For example, the other nicotinic compound can be a compound that binds selectively to the nicotinic receptor subtypes α | 2011-11-10 |
20110274629 | Natural Polymer Blends for Use in Personal Care Products - Embodiments of the present description provide a blend for use in a personal care product having a modified xanthan gum and a galactomannan, wherein the modified xanthan gum is a non-pyruvylated xanthan gum, and the modified xanthan gum and the galactomannan are present in the blend in a ratio from about 1:99 to about 99:1 by weight. Also provided in embodiments of the present description are personal care products having blends of modified xanthan gums and galactomannans, methods for product formulation, and use thereof. | 2011-11-10 |
20110274630 | METHODS AND COMPOSITIONS FOR EXTRACTING FLAVOR AND FRAGRANCE COMPOUNDS AND SOLUBILIZING ESSENTIAL OILS - Provided are methods for extracting flavor and fragrance materials from natural plant materials, using poly(trimethylene ether) glycol homopolymers and copolymers. The poly(trimethylene ether) glycol homopolymers and copolymers act as solubilizers for essential oils, and can be used to provide compositions having a variety of uses in applications such as cosmetics, personal care products, and industrial cleaning products. | 2011-11-10 |
20110274631 | AVERMECTIN/METRONIDAZOLE COMPOSITIONS FOR TREATING AFFLICTIONS OF THE SKIN, E.G., ROSACEA - Pharmaceutical/dermatological compositions containing at least one avermectin compound, e.g., ivermectin and metronidazole or salt, ester or derivative thereof, are useful for treating afflictions of the skin, especially rosacea. | 2011-11-10 |
20110274632 | Sunscreen Cosmetic - The present invention provides a sunscreen cosmetic characteristically comprising | 2011-11-10 |
20110274633 | COMPOSITIONS AND METHODS FOR UV-CURABLE COSMETIC NAIL COATINGS - The present disclosure relates generally to compositions for natural and artificial nail coatings, and particularly, but not by way of limitation, to polymerizable compositions that provide improved adhesion-promoting and improved solvent-susceptibility. | 2011-11-10 |
20110274634 | ALKYL KETAL ESTERS AS DISPERSANTS AND SLIP AGENTS FOR PARTICULATE SOLIDS, METHODS OF MANUFACTURE, AND USES THEREOF - Disclosed herein is a dispersion comprising a liquid or semi-solid continuous phase, a dispersed solid phase comprising a plurality of organic, inorganic or inorganic-organic particles, and an alkyl ketal ester having the structure | 2011-11-10 |
20110274635 | WHITENING COMPOSITION FOR EXTERNAL SKIN APPLICATION CONTAINING OLDENLANDIA DIFFUSA WILLD, RHEUM UNDULATUM, AND BROUSSONETIA KAZINOKI EXTRACT - Disclosed is a whitening composition for external skin application. Containing one or more of | 2011-11-10 |
20110274636 | COMPOSITIONS CONTAINING ACRYLIC THICKENER AND HIGH VISCOSITY NON-SILICONE OIL - The invention relates to a composition, especially a cosmetic composition, comprising at least one acrylic thickener and at least one high viscosity non-silicone oil, as well as to methods of using such compositions. | 2011-11-10 |
20110274637 | Ethylene Oxide Free Antiperspirant/Deodorant Formulations - This invention relates to ethylene oxide free antiperspirant/deodorant formulations comprising at least one antiperspirant/deodorant active ingredient and at least one quaternary polymer having the INCI designation polyquaternium 37. | 2011-11-10 |
20110274638 | OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREON IN HUMAN MEDICINE AND IN COSMETICS - Compounds derived from oxoazetidine corresponding to general formula (I) | 2011-11-10 |
20110274639 | PEPTIDE-BASED COLORING REAGENTS FOR PERSONAL CARE - Peptide-based coloring reagents are described in which a body surface-binding peptide is covalently attached to a pigment, the surface of which is coated with a layer containing at least 3 atom percent of silicon. The peptide-based coloring reagents are useful for coloring body surfaces such as hair, skin, nails, and teeth. | 2011-11-10 |
20110274640 | HAIR TREATMENT AGENTS HAVING LOW-DOSE OLIGOPEPTIDES - Hair treatment agent having advantageous properties containing, based on weight of the agent, 0.00001 to ≦0.05% by weight of at least one oligopeptide having at least one amino acid sequence Glu-Glu-Glu (formula (A)), | 2011-11-10 |
20110274641 | Non-Petrochemically Derived Cationic Emulsifiers That Are Neutralized Amino Acid Esters and Related Compositions and Methods - The invention includes a method of increasing the substantivity of a personal care composition to hair, skin or nails by preparing a composition of an aqueous phase, a non-aqueous phase and a neutralized amino acid ester that is a reaction product of a neutral amino acid having a non-polar side chain with a long chain fatty alcohol and is represented by formula (I): | 2011-11-10 |
20110274642 | Hair Cosmetic - The present invention provides a hair cosmetic composition containing the following ingredients (1) to (4):
| 2011-11-10 |
20110274643 | FRAGRANT FORMULATIONS, METHODS OF MANUFACTURE THEREOF AND ARTICLES COMPRISING THE SAME - Disclosed herein is a fragrant formulation comprising a fragrant composition, and an alkyl ketal ester. Disclosed herein too are methods for manufacturing the fragrant formulation. | 2011-11-10 |
20110274644 | LENS CARE COMPOSITIONS - The present invention provides a lens care composition having a persistent lipid removal efficacy characterized by that the amount of lipids adsorbed by a silicone hydrogel lens after about 10 cycles of soiling with a lipid soiling solution and subsequent cleaning with a lens care solution of the invention under no-rubbing conditions is about 70% or less of that after about 10 cycles of soiling with the lipid soiling solution and subsequent cleaning with an aqueous phosphate buffer under no-rubbing conditions. The lens care composition comprises at least one surfactant, a polyvinylpyrrolidone (PVP), xylitol, a buffering agent, wherein in combination with polyvinylpyrrolidone (PVP) and xylitol, the surfactant provides the persistent lipid removal efficacy. | 2011-11-10 |
20110274645 | Methods of performing medical procedures that promote bone growth, methods of making compositions that promote bone growth, and apparatus for use in such methods - Methods of performing medical procedures, and methods of making bone-growth-promoting compositions useful in performing medical procedures are provided. Apparatus useful both in methods of performing medical procedures, and in methods of making bone-growth-promoting compositions useful in performing medical procedures, are provided. The bone-growth-promoting compositions made according to the disclosed methods are biocompatible, and are adapted to stimulate bone growth when positioned in contact with, or in the vicinity of, a bone of a mammal. | 2011-11-10 |
20110274646 | Compounds and Combinations - The present invention relates to a combination of a hyaluronan oligomer and/or polymer and a factor capable of mobilizing stem cells. The present invention also relates to a method for altering the relative amounts of blood cells and/or the types of blood cells in a subject by administering the combination to the subject. Further, the present invention relates to a method for mobilizing stem cells to the bloodstream of a subject by administering the combination to the subject. Additionally, the present invention relates to a hyaluronan oligomer and/or polymer. | 2011-11-10 |
20110274647 | IL6R/IL6 Chimera for Therapy of Chemotherapy-Induced Peripheral Neuropathy - The invention relates to the use of IL-6R/IL-6 chimera in chemotherapy induced neuropathy. | 2011-11-10 |
20110274648 | Hepatitis C Virus Inhibitors - The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection. | 2011-11-10 |
20110274649 | T-CELL VACCINATION WITH VIRAL VECTORS VIA MECHANICAL EPIDERMAL DISRUPTION - Attenuated, replication-deficient viruses such as vaccinia viruses are used to deliver an exogenous viral, bacterial, parasitic or tumor antigen to an epidermal tissue such as the skin, lungs or gastrointestinal tract, which has been mechanically disrupted, in an amount effective to elicit or stimulate a cell mediated immune response. The epidermal tissue may be mechanically disrupted by a device such as a scarification needle or an abrader device. The epidermis may be mechanically disrupted prior to, at the same time, or immediately after the administration of the vaccine. The vaccine can be used to induce immunity against a pathogen, such as a virus, bacteria, or parasite, or against a cancer in a subject that has or is at risk of developing cancer. In some embodiments a co-stimulatory molecule, a growth factor, an adjuvant and/or a cytokine is administered before, with or after the viral vaccine. In some embodiments, the co-stimulatory molecule is co-expressed with the antigen by the virus. | 2011-11-10 |
20110274650 | COMPOSITIONS AND METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES - Described herein are immunosuppressive molecules including immunosuppressive variants of IL-2, and use of such molecules to treat inflammatory and autoimmune disorders. | 2011-11-10 |
20110274651 | Noscapine and Noscapine Analogs and Their Use in treating Infectious Diseases by Tubulin Binding Inhibition - Compositions and methods for treating or preventing infectious diseases, and inhibiting the ability of microbes to travel within mammalian cells, and inhibiting microbial replication, are disclosed. The compositions include various noscapine analogs, which are capable of blocking the movement of viruses and other microbes within mammalian and other cells by inhibiting the cytoplasmic transport mechanisms within the cells. The compositions described herein include an effective amount of the noscapine analogues described herein, along with a pharmaceutically acceptable carrier or excipient. The compositions can also include one or more additional antimicrobial compounds. | 2011-11-10 |
20110274652 | Methods for Treating Hepatitis C Virus Infection - A method of treating a patient infected with HCV comprises administering to the patient VX-950 and interferon. In the method, an interferon trough level and/or a VX-950 trough level of the patient independently are monitored. The method further includes determining whether or not to adjust: subsequent administration of VX-950 to obtain a minimum target VX-950 trough level of about 1,500 ng/mL; subsequent administration of interferon to obtain a minimum target interferon trough level of about 5,000 pg/mL; or subsequent administration of VX-950 and interferon to obtain said minimum target trough levels. | 2011-11-10 |
20110274653 | DENDRITIC CELL IMMUNORECEPTORS (DCIR)-MEDIATED CROSSPRIMING OF HUMAN CD8+ T CELLS - Immunostimulatory compositions and methods comprising an ITIM motif-containing DC immunoreceptor (DCIR) to mediate potent crosspresentation are described herein. The inventors evaluated human CD8+ T cell responses generated by targeting antigens to dendritic cells (DCs) through various lectin receptors. A single exposure to a low dose of anti-DCIR-antigen conjugate initiated antigen-specific CD8+ T cell immunity by all human DC subsets including ex vivo generated DCs, skin-isolated Langerhans cells and blood mDCs and pDCs. Enhanced specific CD8+ T cell responses were observed when antigens like, FluMP, MART-1, viral (HIV gag), etc. were delivered to the DCs via DCIR, compared to those induced by a free antigen, or antigen conjugated to a control mAb or delivered via DC-SIGN, another lectin receptor. Addition of Toll-like receptor (TLR) 7/8-agonist enhanced DCIR-mediated crosspresentation as well as crosspriming. Thus, antigen targeting via the human DCIR receptor allows activation of specific CD8+ T cell immunity. | 2011-11-10 |
20110274654 | TRIAZOLES AS INHIBITORS OF FATTY ACID SYNTHASE - Provided herein are triazole FASN inhibitors of the formula (I): | 2011-11-10 |
20110274655 | TETRAZOLONES AS INHIBITORS OF FATTY ACID SYNTHASE - Provided herein are tetrazolone FASN inhibitors of the formula (I): | 2011-11-10 |
20110274656 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING HEPATITIS C, COMPRISING THE ROOTS EXTRACT OF PLATYCODON GRANDIFLORUM OR PLATYCODON GRANDIFLORUM SAPONIN COMPONENTS - The present invention relates to a pharmaceutical composition for preventing or treating Hepatitis C, comprising the roots extract of | 2011-11-10 |
20110274657 | OXADIAZOLE DERIVATIVES AS S1P1 RECEPTOR ANTAGONISTS - The present disclosure relates to oxadiazole derivatives of formula (I) as well as pharmaceutical compositions comprising them, and their use in therapy as agonists of the S1P1 receptor. | 2011-11-10 |
20110274658 | CHIMERIC ACTIVATORS: QUANTITATIVELY DESIGNED PROTEIN THERAPEUTICS AND USES THEREOF - Aspects of the invention provide methods for harnessing the potential of proteins that occur naturally (e.g., in humans) and that have serious but finite toxicity. Aspects of the invention relate to a quantitative systems-biological and structural approach to design a class Mof chimeric proteins that avoid the toxicity of protein drugs while retaining their desired activities. In particular, chimeric proteins containing a variant form of a natural protein fused to a targeting moiety may be administered to a subject to target a signal (e.g., induction of apoptosis) to particular cells without having a generalized toxic effect | 2011-11-10 |
20110274659 | Biological control agent for plants - A biological control agent for plants and a method of inoculating the plants with the biological control agent in order protect against plant disease are provided. The treatment method consists of inoculating the plant with a strain of cucumber mosaic virus (CMV), referred to as the KU1 strain, having an associated viral satellite RNA of SEQ ID NO: 1. Particularly, the KU1 strain may be used to protect plants against a particular viral strain of CMV, referred to as the KU2 strain, characterized by the associated viral satellite RNA of SEQ ID NO: 2, which causes tomato necrosis. Additionally, the KU1 strain may be used to protect against potato spindle tuber viroid (PSTV), which causes tomato stunting, fusarium wilt disease in the tomato (caused by | 2011-11-10 |
20110274660 | PHARMACEUTICAL COMPOSITION TO PROTECT AN ANIMAL AGAINST A DISORDER ARISING FROM AN INFECTION WITH A BACTERIUM THAT BELONGS TO THE GROUP OF NOCARDIOFORM ACTINOMYCETES - The invention pertains to a pharmaceutical composition to protect an animal against a disorder arising from an infection with a bacterium that belongs to the group of nocardioform actinomycetes having the ability to survive within macrophages of the animal, comprising live bacteria of a nocardioform actinomycetes species, the live bacteria being attenuated by inactivation of a gene that encodes a protein involved in methylhexahydroindanedione propionate degradation, and a pharmaceutically acceptable carrier for these live bacteria. | 2011-11-10 |
20110274661 | Attentuated Herpesvirus Encoding a Mek Pathway Polypeptide - The disclosure provides materials and methods for the treatment of cells exhibiting a cell proliferative disorder with a herpes simplex virus having a deficiency in the expression of active ICP34.5 and comprising an expression control element effective in modulating at least one component of the MEK pathway to ensure that infected cells are MEK+. Cell proliferative diseases, disorders or conditions, such as cancers, rheumatoid arthritis and macular degeneration, are amenable to treatment using these HSVs. Further provided are methods for preventing such cell proliferative disorders by administering the HSVs as well as methods for ameliorating a symptom associated with a cell proliferative disorder by administering such HSVs. | 2011-11-10 |
20110274662 | Methods of Producing RPE Cells and Compositions of RPE Cells - The present invention provides improved methods for producing RPE cells from human embryonic stem cells or from other human pluripotent stem cells. The invention also relates to human retinal pigmented epithelial cells derived from human embryonic stem cells or other human multipotent or pluripotent stem cells. hRPE cells derived from embryonic stem cells are molecularly distinct from adult and fetal-derived RPE cells, and are also distinct from embryonic stem cells. The hRPE cells described herein are useful for treating retinal degenerative diseases. | 2011-11-10 |
20110274663 | PHARMACEUTICAL COMPOSITION CONTAINING HUMAN MESENCHYMAL STEM CELL - Disclosed are a method for producing a frozen pharmaceutical composition prepared from cultured human mesenchymal stem cells and a pharmaceutical composition containing human mesenchymal stem cells. This method is a method for producing a frozen pharmaceutical composition containing human mesenchymal stem cells, which comprises the following steps in this order: (a) adding trypsin to human mesenchymal stem cells in a culture vessel to detach the cells from the surface of the culture vessel; (b) adding a bicarbonate Ringer's solution containing human serum albumin to the detached cells to terminate the reaction with trypsin, and washing the cells with the bicarbonate Ringer's solution containing human serum albumin; (c) suspending the cells in a bicarbonate Ringer's solution containing human serum albumin and dimethyl sulfoxide; (d) putting the resulting suspension in a container which allows freezing of what is contained therein, and sealing the container; and (e) freezing the suspension put in the container. | 2011-11-10 |
20110274664 | HEPATIC PROGENITOR CELLS AND USES THEREOF - Disclosed are cells, compositions, and methods for treating liver diseases. | 2011-11-10 |
20110274665 | DOSAGE UNIT FORMULATIONS OF AUTOLOGOUS DERMAL FIBROBLASTS - Dosage units consist of an autologous cell therapy product composed of fibroblasts grown for each individual to be treated. The suspension of autologous fibroblasts, grown from a biopsy of each individual's own skin using current good manufacturing practices (CGMP), and standard tissue culture procedures, is supplied in vials containing cryopreserved fibroblasts or precursors thereof, having a purity of at least 98% fibroblasts and a viability of at least 85%, for administration of from one to six mL, preferably two mL, of cells at a concentration of from 1.0-2.0×10 | 2011-11-10 |
20110274666 | METHOD OF ENGRAFTING CELLS FROM SOLID TISSUES - A method of repairing diseased or dysfunctional organs or of establishing a model system of a disease state is provided. For repairing diseased organs, the method involves engraftment of cells from healthy tissue of the diseased or dysfunctional organ admixed with gel-forming biomaterials and nutrient medium, signaling molecules and extracellular matrix components that can be made insoluble rapidly upon transplantation to form a graft. In this way, the graft mimics the complexity of the native microenvironment with a minimum number of components that allow transplantation of cells to successfully engraft, expand and then rebuild part or the entirety of the diseased or dysfunctional organ. In the case of using grafting methods for establishing a disease model, diseased cells may be transplanted in the biomaterials and into experimental hosts. | 2011-11-10 |
20110274667 | METHODS FOR OBTAINING CELL POPULATIONS FROM ADIPOSE TISSUE - Provided herein are methods of efficiently obtaining large numbers of viable, freshly isolated cells from small amounts of adipose tissue, as well as methods of enriching or selecting for target cell populations found therein. In certain embodiments, the method of obtaining a population of cells from adipose tissue comprises incubating the adipose tissue in a solution comprising an enzyme at a concentration which is at least 200 U/ml solution and not more than about 319 U/ml solution. In some embodiments, the method is devoid of any steps which expand the population of cells obtained. In certain aspects, the method further comprises positive or negative selection steps for obtaining an enriched population of target cells from adipose tissue. Related methods of preparing a pharmaceutical composition comprising cells for administration to a patient and methods of treating a disease or medical condition in a patient are further provided herein. | 2011-11-10 |
20110274668 | VOLUME MAINTAINING OSTEOINDUCTIVE/OSTEOCONDUCTIVE COMPOSITIONS - An osteoinductive/osteoconductive composition prepared from a quantity, of demineralized fibrous bone elements possessing an average surface area to volume ratio of about 100:1 to about 20:1, a quantity of mostly shaped regular non-fibrous bone elements possessing an average surface area to volume ratio of about 10:1 or less and a sufficient quantity of biocompatible fluid carrier sufficient to provide the composition as a deformable mass is provided herein. Also provided is a method of using the composition to repair a bone defect site. | 2011-11-10 |
20110274669 | THERAPEUTIC RETROVIRAL VECTORS FOR GENE THERAPY - Retroviral gene therapy vectors that are optimized for erythroid specific expression and treatment of hemoglobinopathic conditions are disclosed. | 2011-11-10 |
20110274670 | MESENCHYMAL STEM CELLS WHICH EXPRESS HUMAN HEPATIC GROWTH FACTOR,MANUFACTURING METHOD THEREOF, AND USE THEREOF AS THERAPEUTIC AGENT FOR LIVER DISEASES - The present invention relates to adult stem cells and a manufacturing method thereof. More specifically, the present invention relates to a recombinant expression vector containing a human hepatic growth factor (hHGF) gene, mesenchymal stem cells which are transformed thereby and express the hHGF, a manufacturing method of the mesenchymal stem cells, conditioned media (CM) which is obtained from the transformed cells and proliferates hepatocytes, a culture method of the mesenchymal stem cells producing the same, and the use of the transformed mesenchymal stem cells and their culture media as an agent for preventing and treating liver diseases. The manufacturing method of the mesenchymal stem cells comprises the steps of: isolating and culturing umbilical cord blood-derived mesenchymal stem cells; transforming the mesenchymal stem cells with the recombinant expression vector; and selecting the mesenchymal stem cells. The mesenchymal stem cells, which produce the hHGF in the present invention effectively, proliferate hepatocytes, suppress apoptosis and effectively suppress liver cirrhosis. Therefore, the mesenchymal stem cell can be widely used in preventing and treating various liver diseases. | 2011-11-10 |
20110274671 | HUMAN PROGENITOR T-CELLS - Human progenitor T cells that are able to successfully engraft a murine thymus and differentiate into mature human T and NK cells are described The human progenitor T cells have the phenotype CD34+CD7+CD1a−CD5− or CD34+CD7+CD1a−CD5+ and are derived from human hematopoietic stem cells, embryonic stem cells and induced pluripotent stem cells b\ coculture with cells expressing a Notch receptor ligand (OP9-DL1 or OP9-DL4) Such cells are useful in a variety of applications including immune reconstitution, the treatment of immunodeficiencies and as carriers for genes used in gene therapy. | 2011-11-10 |
20110274672 | SIALIC ACID PRODUCING BACTERIA - The present invention generally relates to the field of sialic acids, in particular to the field of sialic acid enriched food products and their uses. One embodiment of the present invention relates to a food product enriched with food-grade sialic acid producing bacteria and/or a fraction thereof containing sialic acid. | 2011-11-10 |
20110274673 | Bacillus amyloliquefaciens Strain - The present disclosure relates to a strain of | 2011-11-10 |
20110274674 | ISCHEMIC TISSUE CELL THERAPY - The present invention is directed to compositions and methods for treatment of ischemic diseases and conditions, particularly myocardial, CNS/brain and limb ischemia. More particularly, the present invention provides methods of treating disorders by administering monocytes obtained from blood, including umbilical cord blood, peripheral blood, or bone marrow to an individual in need of treatment, wherein the drug is administered to the individual at a time point specifically determined to provide therapeutic efficacy. In one embodiment, the cells are for injection into ischemic myocardium for the treatment of angina. | 2011-11-10 |
20110274675 | Therapeutically Useful Molecules - A T cell receptor molecule (TCR) containing an alpha chain portion and a beta chain portion wherein the alpha chain portion contains three complementarily determining regions (CDRs): CDR1α: SSYSPS CDR2α: YTSAATL CDR3α: VVSPFSGGGADGLT or comprising or consisting of SPPSGGGADGLT and the beta chain portion contains three complementarity determining regions (CDRs): CDR1β: DFQATT CDR2β: SNEGSKA CDR3β: comprising SARDGGEG or comprising or consisting of RDGGEGSETQY, or wherein up to three amino acid residues in one or more CDRs are replaced by another amino acid residue. The invention also includes polynucleotides encoding the TCR molecules, and host cells containing the said polynucleotides. Patient derived T cells may have the polynucleotides encoding the TCR molecules introduced therein, and the engineered T cells may be introduced into the patient in order to combat a WT1-expressing malignancy. | 2011-11-10 |
20110274676 | Topical Use Of Probiotic Bacillus Spores To Prevent Or Control Microbial Infections - Compositions including an isolated | 2011-11-10 |
20110274677 | Biological Pest Control Mixture Containing D-Limonene and Nutmeg Oil - An organic pest control product comprising nutmeg oil and D-limonene is disclosed. In some embodiments the organic pest control product further comprises a miscibility enhancer to enhance the effectiveness of the product. In some embodiments the miscibility enhancer can comprise a liquid soap or detergent. Additional formulations that comprise cassia oil and/or eucalyptus oil are also disclosed. A method of use of an organic pest control product is also disclosed, in which the organic pest control product is effective to control a wide range of biological pests including fungi, bacteria, and insects, including those responsible for Dutch Elm Disease, fire blight, and Colony Collapse Disorder. | 2011-11-10 |
20110274678 | Beverage - A nutritional beverage composition for providing nutrition to a patient suffering from a kidney ailment comprises a flavor component and a natural sweetener, and is further characterized in that it does not contain amounts of particular ingredients that may not be desirable in treating kidney ailments. In one embodiment of the present invention, the beverage composition lacks substantially any potassium, phosphorous, magnesium, high fructose corn syrup, vitamin A, vitamin K, or vitamin E. | 2011-11-10 |
20110274679 | Compositions and Methods of SIRT Activation - Compositions and methods of SIRT activation are presented in which one or more vitamin compounds, and especially vitamin B compounds are used to significantly increase SIRT activity in vitro and in vivo. In especially preferred compositions, vitamin B6, vitamin B12, and vitamin B2 are present in synergistic quantities. | 2011-11-10 |
20110274680 | Chemical composition and its delivery for lowering the risks of alzheimer's, cardiov ascular and type-2 diabetes diseases - Synergistic chemical compositions of bioactive compounds in a dietary supplement for lowering the risks of Alzheimer's, Cardiovascular and Diabetes diseases; chemical compositions of a sugar free super sweetener for people with Type-2 Diabetes disease and a targeted nano delivery of bioactive compounds and/or bioactive molecules are described. Furthermore, microelectro-mechanical system (Mems) based passive and active (based on feedback diagnostics data) delivery systems and methods of bioactive compounds and/or bioactive molecules are also described. | 2011-11-10 |
20110274681 | HUMAN E3ALPHA UBIQUITIN LIGASE FAMILY - The present invention relates to a novel polypeptide encoding a protein which is the full length human ortholog of E3α ubiquitin ligase. The invention also relates to vector, host cells, antibodies and recombinant methods for producing the polypeptide. In addition, the invention discloses therapeutic, diagnostic and research utilities for these and related products. | 2011-11-10 |
20110274682 | METHODS FOR PROTEASE ASSISTED PROTEIN DELIVERY - A method for intracellular delivery of single proteins or other cargo molecules by encapsulation within nanocapsules formed by interfacial polymerization of one or more types of monomers and selected protease cleavable cross-linkers is provided. The thin positively charged capsules are readily brought into the cytosol of target cells by endocytosis. The capsules are degraded by the action of endogenous proteases or co-delivered proteases on the cross-linkers releasing the functional cargo unaltered. The cross-linkers can be adapted to be cleavable by specific enzymes selected from available intracellular enzymes within the target cell or co-delivered or self-cleaving when the cargo itself is a protease. The nanocapsules produced by the methods have been shown to have long-term stability, high cell penetration capability, low toxicity and efficient protease-modulated specific degradability without affecting cargo protein function. | 2011-11-10 |
20110274683 | Antibodies That Bind CSF1R - Antibodies that bind CSF1R are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind CSF1R are also provided. Polynucleotides encoding antibodies to CSF1R are provided. Polynucleotides encoding antibody heavy chains and lights chains are also provided. Methods of treatment using antibodies to CSF1R are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis, bone loss, and multiple sclerosis. | 2011-11-10 |
20110274684 | CYTOTOXIC ANTIBODIES DIRECTED AGAINST ANTIBODIES INHIBITING FACTOR VIII - The invention relates to an anti-idiotypical antibody targeting an antibody inhibiting the human fact VIII, said inhibiting antibody targeting the C2 region of the human factor VIII, the variable region of each of the light chains thereof being encoded by a sequence of nucleic acids of which at least 70% is identical to the murine sequence of nucleic acids SEQ ID NO: 1, and the variable region of each of the heavy chains thereof being encoded by a sequence of nucleic acids of which at least 70% is identical to the murine sequence of nucleic acids SEQ ID NO: 2, the constant regions of the light chains and the heavy chains being constant regions from a non-murine species. The invention also relates to the use of said antibody for activating the FcγRIII receptors of cytotoxic immune cells, and to the production of a medicament especially for the treatment of haemophilia A. | 2011-11-10 |
20110274685 | ANTIBODIES THAT BIND HUMAN CD27 AND USES THEREOF - Isolated monoclonal antibodies which bind to human CD27 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies. | 2011-11-10 |
20110274686 | ANTITUMOR COMBINATIONS CONTAINING ANTIBODIES RECOGNIZING SPECIFICALLY CD38 AND MELPHALAN - Pharmaceutical composition comprising an antibody specifically recognizing CD38 and melphalan. | 2011-11-10 |
20110274687 | METHODS OF TREATING TSLP-RELATED INFLAMMATORY DISORDERS - The present disclosure provides compositions and methods relating to antigen binding proteins which bind to human thymic stromal lymphopoietin (TSLP), including antibodies. In particular embodiments, the disclosure provides fully human, humanized and chimeric anti-TSLP antibodies and derivatives of such antibodies. The disclosure further provides nucleic acids encoding such antibodies and antibody fragments and derivatives, and methods of making and using such antibodies including methods of treating and preventing TSLP-related inflammatory and fibrotic disorders. | 2011-11-10 |
20110274688 | PREVENTION OF TUMORS WITH MONOCLONAL ANTIBODIES AGAINST NEU - Methods of preventing the transformation of a normal cell into a tumor cell that has p185 on its surface are disclosed. The methods comprise administering an antibody which specifically binds to p185. Methods of preventing the transformation of a normal cell into a tumor cell that has p185 on its surface in an individual at high risk of developing tumors are disclosed. | 2011-11-10 |
20110274689 | COMPOUNDS AND METHODS TO MEASURE METABOLIC FUNCTION AND RESTORE NORMAL METABOLIC FUNCTION - The invention relates to treatment to restore normal metabolic function, including but not limited to normal glucose levels. The invention in one embodiment contemplates methods of reducing elevated glucose levels in subjects with elevated glucose levels by administering a composition comprising at least a portion of human Sfrp5. The invention in one embodiment contemplates methods of reducing elevated glucose levels in subjects with elevated glucose levels by administering a composition comprising an inhibitor of Wnt5a, including but not limited to an antibody inhibitor. | 2011-11-10 |
20110274690 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR - The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same. | 2011-11-10 |
20110274691 | FERROPORTIN ANTIBODIES AND METHODS OF USE - Compositions for treating disorders of iron homeostasis are provided. More particularly, anti-ferroportin antibodies, compositions containing such antibodies, corresponding nucleic acids, vectors and host cells, and methods of making such antibodies are provided. | 2011-11-10 |
20110274692 | Screening Methods - The present invention provides polypeptide binding agents, e.g. antibodies, that exhibit the ability to kinetically modulate the binding and signaling of biological signaling complexes, e.g., receptor-ligand complexes; methods of identifying such polypeptide binding agents, methods of making such polypeptide binding agents, compositions comprising such polypeptide binding agents, and methods of using such polypeptide binding agents. | 2011-11-10 |
20110274693 | STAPHYLOCOCCUS AUREUS LEUKOCIDINS, THERAPEUTIC COMPOSITIONS, AND USES THEREOF - Disclosed herein are isolated and purified | 2011-11-10 |
20110274694 | ERK1/2 Posphorylation Site Specific Antibody - The invention relates to an antibody specific to Erk1/2 phosphorylated at Thr188 and a method for producing the same. The invention also relates to an in vitro method for determining the presence of phosphorylated Erk1/2 in a sample using the antibody of the invention. Therefore, the invention also comprises an assay for diagnosing a heart disease in vitro comprising the antibody of the invention and certain uses of the antibody. Moreover the invention relates to a peptide used to produce the antibody. | 2011-11-10 |
20110274695 | PRODRUGS CONTAINING NOVEL BIO-CLEAVABLE LINKERS - The invention provides the compounds of formula (I) or pharmaceutically acceptable salts thereof. The invention also provides pharmaceutical compositions comprising one or more compounds of formula I or intermediates thereof and one more of pharmaceutically acceptable carriers, vehicles or diluents. The invention further provides methods of preparation and methods of use of prodrugs including NO-releasing prodrugs, double prodrugs and mutual prodrugs comprising the compounds of formula I. | 2011-11-10 |
20110274696 | ANTIBODIES TO CCR2 - Provided are antibodies including human antibodies and antigen-binding portions thereof that specifically bind to CCR2, specifically human CCR2, and that may function to inhibit CCR2. Anti-CCR2 antibodies include those which bind to the first and/or second extracellular loops of CCR2. Also provided are human anti-CCR2 antibodies and antigen-binding portions thereof. Isolated heavy and light chain immunoglobulins derived from human anti-CCR2 antibodies and nucleic acid molecules encoding such immunoglobulins are provided. Methods of making human anti-CCR2 antibodies or antigen-binding portions, compositions comprising these antibodies or antigen-binding portions, methods of using the antibodies and antigen-binding portions, and compositions for diagnosis and treatment are provided. Also provided are gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-CCR2 antibodies or antigen binding portions thereof | 2011-11-10 |
20110274697 | NOVEL USES - The present invention relates generally to the use of bendamustine in combination with an anti-CD20 antibody to treat cancer. | 2011-11-10 |
20110274698 | Immunomodulation Of Inflammatory Conditions Utilizing Follistatin-Like Protein-1 And Agents That Bind Thereto - Follistatin-like protein (FSTL-1) is a secreted glycoprotein of unknown function, first isolated from mouse osteoblastic cells as a transforming growth factor-β1-inducible gene. The inventors have discovered that FSTL-1 is a proinflammatory mediator. As such, the invention provides for composition and methods of using agents that bind to FSTL-1 to modulate various types of inflammation (e.g., autoimmune diseases). Inhibitors and antagonists of FSTL-1, particularly antibodies or antibody fragments, may be used to treat conditions related to inflammation, such as arthritis. In addition, the inventors have discovered that FSTL-1 has a role in the Th17 pathway. Accordingly, the invention provides for compositions and methods of using agents which bind to FSTL-1 to modulate the generation of Th17 cells. Such agents are useful for delaying development of and treating diseases associated with undesired production of Th17 cells, such as autoimmune diseases. Furthermore, since FSTL-1 is a proinflammatory mediator with a role in cancer, the invention provides for compositions and methods of using a pharmaceutical composition of FSTL-1 to delay development of or treat cancer. | 2011-11-10 |
20110274699 | ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE beta (HPTPbeta) AND USES THEREOF - Antibodies and antigen binding fragments thereof that bind to human protein tyrosine phosphatase beta (HPTPβ), and uses thereof. | 2011-11-10 |
20110274700 | POLY-N-ACETYL GLUCOSAMINE (PNAG/dPNAG)-BINDING PEPTIDES AND METHODS OF USE THEREOF - The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as | 2011-11-10 |
20110274701 | COMPOSITION AND METHOD FOR PREVENTING/DECREASING RESPIRATORY ILLNESS - A microbial adherence inhibitor in the form of fowl egg antibodies is disclosed, along with the method of making it and methods of using it. The inhibitor functions by substantially preventing the attachment of adherence of colony-forming immunogens in the respiratory tracts of host animals and humans. The inhibitor is made by inoculating female birds with the immunogen, harvesting the eggs which contain antibodies to the immunogen, and separating the yolk and albumin from the shells of the eggs. The yolk and albumin contents are administered to animals or human by distributing the contents directly or introducing the contents entrained in air. The adherence inhibiting material can be formulated for use in a variety of ways such as an oral spray or a nasal spray. These formulations can be effective to prevent or reduce respiratory illnesses in animals and humans. | 2011-11-10 |
20110274702 | NEUTRALIZING ANTI-INFLUENZA A VIRUS ANTIBODIES AND USES THEREOF - The invention relates to antibodies, and antigen binding fragments thereof, that specifically bind to an epitope in the stem region of an influenza A hemagglutinin trimer and neutralize a group 1 subtype and a group 2 subtype of influenza A virus. The invention also relates to nucleic acids that encode, immortalized B cells and cultured single plasma cells that produce, and to epitopes that bind to such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, treatment and prevention of influenza A virus infection. | 2011-11-10 |
20110274703 | DETECTION AND TREATMENT OF NON-DERMAL FIBROSIS - The invention relates to methods for the diagnosis, prognosis, and treatment of non-dermal fibrosis, including lung (or pulmonary) fibrosis. | 2011-11-10 |
20110274704 | Compositions and Methods of Use of Immunotoxins Comprising Ranpirnase (Rap) Show Potent Cytotoxic Activity - The present invention concerns methods and compositions for forming immunotoxin complexes having a high efficacy and low systemic toxicity. In preferred embodiments, the toxin moiety is a ranpirnase (Rap), such as Rap(Q). In more preferred embodiments, the immunotoxin is made using dock-and-lock (DNL) technology. The immunotoxin exhibits improved pharmacokinetics, with a longer serum half-life and significantly greater efficacy compared to toxin alone, antibody alone, unconjugated toxin plus antibody or even other types of toxin-antibody constructs. In a most preferred embodiment the construct comprises an anti-Trop-2 antibody conjugated to Rap, although other combinations of antibodies, antibody fragments and toxins may be used to form the subject immunotoxins. The immunotoxins are of use to treat a variety of diseases, such as cancer, autoimmune disease or immune dysfunction. | 2011-11-10 |
20110274705 | METHODS AND COMPOSITIONS TO GENERATE AND CONTROL THE EFFECTOR PROFILE OF T CELLS BY SIMULTANEOUS LOADING AND ACTIVATION OF SELECTED SUBSETS OF ANTIGEN PRESENTING CELLS - The present invention is directed to novel compositions that cause effective redirection of class I-immunity to Tc1 effectors, that take advantage of the unexpected loading of MHC I by peptide within IgG backbone combined with appropriate instruction of antigen presenting cells. Such compositions are able to transform a seemingly ineffective therapeutics into a highly effective one, associated with generation of class I-restricted cytolytic cells and IFN-γ, IL-2 producing T cells, further associated with protection against a highly virulent microbe or recovery from malignant tumoral process. | 2011-11-10 |
20110274706 | NUCLEIC ACID DELIVERY VEHICLE AND USES THEREOF - A nucleic acid-delivery vehicle for delivering nucleic acids to target cells is provided. The nucleic acid-delivery vehicle comprises a plurality of nanoparticles; and a plurality of nucleic acids. The nanoparticles further comprises one or more signal peptides attached to the nanoparticles. The nanoparticles and the nucleic acids are agglomerated to form a nucleic acid-granulation particle having a dimension of at least 20 nm. Methods of making the nucleic acid-delivery vehicle and kits comprising nucleic acid-delivery vehicle are also provided. | 2011-11-10 |
20110274707 | COMPOSITION FOR IMPROVING INFLAMMATORY DISEASE USING ABH ANTIGENS - The present invention relates to a composition for improving inflammatory disease, and more specifically to a composition for improving inflammatory disease able to improve inflammatory reactions and the barrier function of epithelial tissue such as the skin, to enhance aging resistance and skin elasticity and to prevent or treat aging. The present invention makes it possible to control inflammatory reactions by modulating the expression and modulating the activity of ABH antigens, and thus the composition of the present invention can be employed as a development marker for therapeutic agents designed to soothe or treat or help in the treatment of disease caused by inflammatory reaction in body tissue and notably the skin expressed by ABH antigens, and can be used in the development of external preparations and cosmetics containing external preparations designed for the purposes such as restoration of normal function and moisturization, wrinkle enhancement, whitening and elasticity recovery in skin through modulation of differentiation of keratinocytes and the skin barrier function. | 2011-11-10 |
20110274708 | SHORT-FORM HUMAN MD-2 AS A NEGATIVE REGULATOR OF TOLL-LIKE RECEPTOR 4 SIGNALING - The present invention is based on a novel, alternatively spliced human isoform of MD-2 (MD-2s). In addition, the present invention relates to modified MD-2 proteins, wherein one or more tyrosine residues have been mutated to phenylalanine. In various embodiments, the invention relates to methods and kits for preventing, reducing the likelihood of developing and/or treating various conditions using MD-2s. The invention also describes methods of determining the risk of a subject to various conditions. | 2011-11-10 |
20110274709 | T-Cell Immunogens Derived from Anti-Viral Proteins and Methods of Using Same - Isolated polypeptides related to endogenous anti-viral polypeptides; and compositions, including immunogenic compositions, comprising a subject isolated polypeptide are disclosed herein. A subject isolated polypeptide comprises an amino acid sequence having substantial amino acid sequence identity to a contiguous stretch of amino acids of one or more endogenous anti-viral polypeptides, wherein the endogenous anti-viral polypeptides are polypeptides subject to proteolytic degradation as a result of the activity of one or more viral proteins. Also provided are diagnostic and treatment methods using the subject isolated polypeptides and compositions. | 2011-11-10 |
20110274710 | PCV2 IMMUNOGENIC COMPOSITIONS AND METHODS OF PRODUCING SUCH COMPOSITIONS - An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time-consuming extraction procedures required to separate and recover the recombinant protein from within the cells. | 2011-11-10 |
20110274711 | HLA-G POLYPEPTIDES AND PHARMACEUTICAL USES THEREOF - The present invention relates to novel proteins and pharmaceutical uses thereof The invention more specifically relates to novel proteins comprising the sequence of an HLA-5 antigen fused to the sequence of a b2 microglobulin. The invention also relates to methods of producing such polypeptides, pharmaceutical compositions comprising the same, as well as their uses for treating various diseases including organ/tissue rejection. | 2011-11-10 |
20110274712 | ANTIGENIC COMPOSITIONS - The invention relates to antigenic compositions and to methods for immunising animals using same. The antigenic compositions comprises a lipid formulation most usually in solid form, and at least one antigenic component. A preferred antigenic component is a living organism. In a preferred embodiment the composition is formulated for oral administration. | 2011-11-10 |
20110274713 | ANTIGEN-PRESENTING SCAFFOLDS - The invention relates to compounds having formula (I): Scaffold-[L-(Antigen) | 2011-11-10 |
20110274714 | Broad Spectrum Vaccine Against Non-Typhoidal Salmonella - The present invention is drawn to attenuated | 2011-11-10 |
20110274715 | Methods and compositions for cooling the human body - Cooling of the human body is accomplished by topical application of a treatment composition including an extract of a green marine algae. A preferred green marine algae is | 2011-11-10 |
20110274716 | COMPOSITIONS CONTAINING FUCOXANTHIN EXTRACT - A composition comprises extract of fucoxanthin, wherein said composition further comprises tocotrienols and/or fucoidan. Said composition can be used to treat obesity. Said composition shows outstanding effect of weight loss. There is outstanding synergy effect among those constituents of the composition. | 2011-11-10 |
20110274717 | POLYSACCHARIDE CONJUGATION WITH DETOXIFIED E. coli HEAT LABILE ENTEROTOXIN (LT) USED AS VACCINE - A detoxified recombinant | 2011-11-10 |